Analysis of therapeutic proteins and peptides using multiangle light scattering coupled to ultra high performance liquid chromatography.
Analysis of the physical properties of biotherapeutic proteins is crucial throughout all the stages of their lifecycle. Herein, we used size-exclusion ultra high performance liquid chromatography coupled to multiangle light scattering and refractive index detection systems to determine the molar mass, mass-average molar mass, molar-mass dispersity and hydrodynamic radius of two monoclonal antibodies (rituximab and trastuzumab), a fusion protein (etanercept), and a synthetic copolymer (glatiramer acetate) employed as models. A customized instrument configuration was set to diminish band-broadening effects and enhance sensitivity throughout detectors. The customized configuration showed a performance improvement with respect to the high-performance liquid chromatography standard configuration, as observed by a 3 h column conditioning and a higher resolution analysis in 20 min. Analysis of the two monoclonal antibodies showed averaged values of 148.0 kDa for mass-average molar mass and 5.4 nm for hydrodynamic radius, whereas for etanercept these values were 124.2 kDa and 6.9 nm, respectively. Molar-mass dispersity was 1.000 on average for these proteins. Regarding glatiramer acetate, a molar mass range from 3 to 45 kDa and a molar-mass dispersity of 1.304 were consistent with its intrinsic peptide diversity, and its mass-average molar mass was 10.4 kDa. Overall, this method demonstrated an accurate determination of molar mass, overcoming the difficulties of size-exclusion chromatography.
Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán, Unidad de Investigación y Desarrollo, Tenancingo, México.
Carlos E
CE
Espinosa-de la Garza
Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán, Unidad de Investigación y Desarrollo, Tenancingo, México.
Mariana P
MP
Miranda-Hernández
Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán, Unidad de Investigación y Desarrollo, Tenancingo, México.
Lilia
L
Acosta-Flores
Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán, Unidad de Investigación y Desarrollo, Tenancingo, México.
Néstor O
NO
Pérez
Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán, Unidad de Investigación y Desarrollo, Tenancingo, México.
Luis F
LF
Flores-Ortiz
Probiomed S.A. de C.V. Cruce de carreteras Acatzingo-Zumpahuacán, Unidad de Investigación y Desarrollo, Tenancingo, México.
Emilio
E
Medina-Rivero
D002851:Chromatography, High Pressure Liquid; D000068800:Etanercept / Q000737:chemistry*; D000068717:Glatiramer Acetate / Q000032:analysis*; D057446:Hydrodynamics; D008027:Light; D000069283:Rituximab / Q000032:analysis*; D012542:Scattering, Radiation; D000068878:Trastuzumab / Q000032:analysis*
D000069283:Rituximab; D000068717:Glatiramer Acetate; D000068800:Etanercept; D000068878:Trastuzumab
Biotherapeutic proteins; Hydrodynamic radius; Multiangle light scattering; Synthetic copolymers; Ultra high performance liquid chromatography